Brief: Genfit Says NIS4 Identifies Patients With 'At-Risk' NASH

Genfit SA

19/11/2021 07:52

Nov 19 (Reuters) - GENFIT SA  GNFT.PA :
    * GENFIT ANNOUNCED ON THURSDAY FNIH NIMBLE STUDY
DEMONSTRATES NIS4
TECHNOLOGY'S UNIQUE PERFORMANCE IN IDENTIFYING PATIENTS WITH
"AT-RISK" NON-ALCOHOLIC STEATOHEPATITIS (NASH)
    * RECOGNITION IN A STAGE 1 STUDY UNDERTAKEN BY NON-INVASIVE
BIOMARKERS OF METABOLIC LIVER DISEASE (NIMBLE) INITIATIVE OF THE
FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH'S BIOMARKERS
CONSORTIUM
    * STUDY ALSO PROVIDED EVIDENCE THAT NIS4 TECHNOLOGY HAD THE
BEST
RESULTS FOR THE DIAGNOSIS OF FIBROSIS STAGE ≥ 2

Source text for Eikon:  ID:nGNX6G1j3x 
Further company coverage:  GNFT.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))